HOME
PRODUCTS
COMPANY
CONTACT
FAQ
Research
Dictionary
Pharma
Sign Up
FREE
or
Login
Username:
Password:
Remember login
Login
Send password reminder...
BCH 2763
Also Known As:
BCH-2763; Phe-Pro-(NH(CH2)4CO)2-Asp-Phe-Glu-Pro-Ile-Pro-Leu; phenylalanyl-prolyl-(NH(CH2)4CO)2-aspartyl-phenylalanyl-glutamyl-prolyl-isoleucyl-prolyl-leucine
Networked:
2
relevant articles (
1
outcomes,
1
trials/studies)
Relationship Network
Bio-Agent Context: Research Results
Amino Acids, Peptides, and Proteins: 1
Peptides: 82426
Oligopeptides: 519
BCH 2763: 2
Related Diseases
1.
Venous Thrombosis (Deep-Vein Thrombosis)
06/01/1999 - "
In conclusion, the results of this study indicate that BCH 2763 is an effective intravenous antithrombotic agent in the canine electrolytic injury model of venous thrombosis.
"
06/01/1999 - "
Antithrombotic effects of BCH 2763, a new direct thrombin inhibitor, in a canine model of venous thrombosis.
"
02/01/1998 - "
BCH-2763 is effective at lower doses than the other direct thrombin inhibitors and for venous thrombosis at a smaller aPTT increase.
"
02/01/1998 - "
All the direct thrombin inhibitors caused similar shifts in aPTT at doses required to inhibit arterial thrombosis, but BCH-2763 inhibited venous thrombosis at lower aPTT fold increases.
"
02/01/1998 - "
In venous thrombosis the doses required for full efficacy were substantially lower for the bivalent (BCH-2763: 0.12; r-hirudin: 0.12; hirulog: 0.18) than for the catalytic site-directed (inogatran: 0.48; argatroban: 0.90) thrombin inhibitors; the dose required for heparin was 0.19.
"
2.
Thrombosis (Thrombus)
02/01/1998 - "
All the direct thrombin inhibitors caused similar shifts in aPTT at doses required to inhibit arterial thrombosis, but BCH-2763 inhibited venous thrombosis at lower aPTT fold increases.
"
02/01/1998 - "
The rank order of potency based on doses (mg/kg/h) required for full efficacy against arterial thrombosis was BCH-2763 (1.2) > inogatran (1.5) > r-hirudin (1.8) > hirulog (3.3) > argatroban (> 3.0); heparin required a markedly higher dose (5.7).
"
Related Drugs and Biologics
1.
Antithrombins
2.
Thrombin
3.
Hirudins
4.
Heparin (Liquaemin)
5.
inogatran
6.
bivalirudin (Angiomax)
7.
argatroban (MPQA)
8.
Fibrinolytic Agents (Antithrombotic Agents)